- Investopedia•16 hours ago
Roche filed suit to fend off competition from Amgen’s biosimilar for its bestselling drug Avastin.
- Market Realist•18 hours ago
Despite Amgen's efforts to improve access for Repatha, the drug has seen high rejection rates in the US due to stringent preauthorization requirements.
- Market Realist•19 hours ago
In 2016, Neulasta’s sales totaled ~$4.6 billion, which is a YoY drop of ~1.4%, mainly due to reduced usage of myelosuppressive chemotherapy agents by cancer patients.
AMGN : Summary for Amgen Inc. - Yahoo Finance
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
|Bid||171.43 x 300|
|Ask||173.40 x 200|
|Day's Range||168.89 - 173.36|
|52 Week Range||133.64 - 176.85|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||16.92|
|Dividend & Yield||4.60 (2.65%)|
|1y Target Est||N/A|